SCHEDULE: Fortress Biotech CEO Boosts Stake to 20.7%

Fortress Biotech's CEO, Lindsay A. Rosenwald, M.D., increased his beneficial ownership to 20.7% of the company's common stock following recent equity grants.

Summary

• Lindsay A. Rosenwald, M.D., President and CEO of Fortress Biotech, Inc., beneficially owns 6,917,715 shares of common stock.
• This represents approximately 20.7% of the outstanding common stock, based on 31,037,937 shares as of December 11, 2025.
• The beneficial ownership includes 475,424 shares of unvested restricted common stock granted on March 18, 2026, and 454,153 shares granted on January 1, 2025, both under the Long Term Incentive Plan (LTIP).
• These grants were awarded because the Reporting Person achieved 100% of relevant goals and objectives set by the Compensation Committee of the Issuer's Board.
• The total beneficial ownership also comprises 4,050,765 currently issued and outstanding shares, 2,330,874 shares underlying currently exercisable warrants, 49,524 shares held by Paramount Biosciences, LLC, and 11,398 shares held by Capretti Grandi LLC.
• The reported amount excludes 96,919 shares held in family trusts over which the Reporting Person does not have voting or dispositive control.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive development, reflecting strong insider confidence and successful achievement of performance targets by the CEO, which aligns management incentives with shareholder value.

Positives

• CEO Lindsay A. Rosenwald, M.D., was granted significant equity (475,424 shares on March 18, 2026, and 454,153 shares on January 1, 2025) due to achieving 100% of performance goals.
• The CEO's increased beneficial ownership to 20.7% demonstrates strong alignment of interests with shareholders.
• The grants are part of a Long Term Incentive Plan, indicating a structured approach to executive compensation tied to performance.

Risks

• The 475,424 shares of restricted common stock granted on March 18, 2026, and the 454,153 shares granted on January 1, 2025, are subject to repurchase by the Issuer until vested, as set forth in the LTIP and Award Agreement, implying a vesting schedule and potential forfeiture if conditions are not met.

Future Outlook

The filing states that the Reporting Person does not have any present plans or proposals that would result in significant corporate transactions, changes in management, capitalization, dividend policy, business structure, or other actions that could impede acquisition of control or de-listing of securities.

Management Comments

• The Reporting Person was granted the shares of Common Stock... upon the determination that the Reporting Person had achieved 100% of the relevant goals and objectives established by the Compensation Committee of the Issuer's Board.

Industry Context

StockSavvy.ai notes that an increase in insider ownership, especially by a CEO, is generally viewed positively in the biotech sector as it signals strong confidence in the company's future prospects and aligns management's interests with those of shareholders. This is particularly relevant in biotech where long-term development cycles and regulatory hurdles require sustained commitment.

Comparison to Industry Standards

• While specific comparable companies or projects are not detailed in this filing, StockSavvy.ai observes that executive compensation tied to performance metrics, as seen with Fortress Biotech's LTIP, is a standard practice across the biotech industry.
• A 20.7% beneficial ownership stake for a CEO is a substantial holding, often exceeding typical insider ownership percentages in larger, more mature biotech firms, indicating a high level of personal investment in the company's success.

Related Party Transactions

• The Reporting Person has voting and dispositive control over shares held by Paramount Biosciences, LLC and Capretti Grandi LLC, which are included in his beneficial ownership.

Stakeholder Impact

• Shareholders: Increased alignment of CEO's interests with shareholders due to significant and performance-based equity grants.
• Employees: The Long Term Incentive Plan provides a framework for performance-based compensation, potentially motivating other key personnel.

Next Steps

• Continued vesting of restricted shares granted under the Long Term Incentive Plan.
• Ongoing operation of the Issuer's business as the Reporting Person has no present plans for extraordinary corporate transactions or changes.

Key Dates

Recommendation

The filing indicates strong insider confidence and successful performance by the CEO, which are positive signals. However, this is primarily an ownership disclosure and does not contain new operational or financial results that would warrant a 'buy' recommendation without further analysis of the company's core business and financial performance. The increased insider stake suggests stability and alignment, supporting a 'hold' position for existing investors.

Keywords

Fortress Biotech, Lindsay A. Rosenwald, Schedule 13D, Beneficial Ownership, CEO Stock Grant, Long Term Incentive Plan, Restricted Stock, Executive Compensation, Insider Ownership, Biotech